Large-scale chemical dissection of mitochondrial function

Nature Biotechnology

Volumn 26, Issue 3, 2008, Pages 343-351

  Wagner, Bridget K ^a   Kitami, Toshimori ^a,b   Gilbert, Tamara J ^a   Peck, David ^a   Ramanathan, Arvind ^a   Schreiber, Stuart L ^a   Golub, Todd R ^a,c   Mootha, Vamsi K ^a,b,d  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOASSAY; BIOTECHNOLOGY; CELL CULTURE; GENE EXPRESSION; PERTURBATION TECHNIQUES; PROTEINS;

MITOCHONDRIAL BIOLOGY; MITOCHONDRIAL OXIDATIVE PHOSPHORYLATION (OXPHOS); NOVEL THERAPEUTICS; PROTEIN SYNTHESIS;

MITOCHONDRIA;

ESTROGEN RELATED RECEPTOR ALPHA; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MITOCHONDRIAL DNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; PROPRANOLOL; PROTEIN SYNTHESIS INHIBITOR; REACTIVE OXYGEN METABOLITE; STATIN;

ARTICLE; CELL ASSAY; DEGENERATIVE DISEASE; DNA TRANSCRIPTION; GENE EXPRESSION; HOMEOSTASIS; MITOCHONDRIAL RESPIRATION; MITOCHONDRIAL TOXICITY; MITOCHONDRION; MUSCLE FIBER CULTURE; MYOPATHY; PRIORITY JOURNAL;

ANIMALS; CELL LINE; CELL NUCLEUS; DNA, MITOCHONDRIAL; DRUG TOXICITY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENOME; MICE; MICROTUBULES; MITOCHONDRIA; MOLECULAR STRUCTURE; OXIDATIVE PHOSPHORYLATION; PHARMACEUTICAL PREPARATIONS; REACTIVE OXYGEN SPECIES; TRANSCRIPTION, GENETIC; TUBULIN MODULATORS;

EID: 40449112930     PISSN: 10870156     EISSN: 15461696     Source Type: Journal    
DOI: 10.1038/nbt1387     Document Type: Article

References (50)

1. Anderson, S. et al. Sequence and organization of the human mitochondrial genome. Nature 290, 457-465 (1981).
2. Chance, B. & Williams, G.R. Respiratory enzymes in oxidative phosphorylation. III. The steady state. J. Biol. Chem. 217, 409-427 (1955).
3. DiMauro, S. & Schon, E.A. Mitochondrial respiratory-chain diseases. N. Engl. J. Med. 348, 2656-2668 (2003).
4. Mootha, V.K. et al. PGC-1α-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat. Genet. 34, 267-273 (2003).
5. Petersen, K.F. et al. Mitochondrial dysfunction in the elderly: possible role in insulin resistance. Science 300, 1140-1142 (2003).
6. Balaban, R.S., Nemoto, S. & Finkel, T. Mitochondria, oxidants, and aging. Cell 120, 483-495 (2005).
7. Kelly, D.P. & Scarpulla, R.C. Transcriptional regulatory circuits controlling mitochondrial biogenesis and function. Genes Dev. 18, 357-368 (2004).
8. Weinstein, J.N. et al. An information-intensive approach to the molecular pharmacology of cancer. Science 275, 343-349 (1997).
9. Hughes, T.R. et al. Functional discovery via a compendium of expression profiles. Cell 102, 109-126 (2000).
10. Lamb, J. et al. The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science 313, 1929-1935 (2006).
11. Ramanathan, A., Wang, C. & Schreiber, S.L. Perturbational profiling of a cell-line model of tumorigenesis by using metabolic measurements. Proc. Natl. Acad. Sci. USA 102, 5992-5997 (2005).
12. Leary, S.C., Battersby, B.J., Hansford, R.G. & Moyes, C.D. Interactions between bioenergetics and mitochondrial biogenesis. Biochim. Biophys. Acta 1365, 522-530 (1998).
13. Dolma, S., Lessnick, S.L., Hahn, W.C. & Stockwell, B.R. Identification of genotype-selective antitumor agents using synthetic lethal chemical screening in engineered human tumor cells. Cancer Cell 3, 285-296 (2003).
14. Smiley, S.T. et al. Intracellular heterogeneity in mitochondrial membrane potentials revealed by a J-aggregate-forming lipophilic cation JC-1. Proc. Natl. Acad. Sci. USA 88, 3671-3675 (1991).
15. Berridge, M.V. & Tan, A.S. Characterization of the cellular reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT): subcellular localization, substrate dependence, and involvement of mitochondrial electron transport in MTT reduction. Arch. Biochem. Biophys. 303, 474-482 (1993).
16. Crouch, S.P., Kozlowski, R., Slater, K.J. & Fletcher, J. The use of ATP bioluminescence as a measure of cell proliferation and cytotoxicity. J. Immunol. Methods 160, 81-88 (1993).
17. Ye, G., Metreveli, N.S., Ren, J. & Epstein, P.N. Metallothionein prevents diabetes-induced deficits in cardiomyocytes by inhibiting reactive oxygen species production. Diabetes 52, 777-783 (2003).
18. Stegmaier, K. et al. Gene expression-based high-throughput screening (GE-HTS) and application to leukemia differentiation. Nat. Genet. 36, 257-263 (2004).
19. Peck, D. et al. A method for high-throughput gene expression signature analysis. Genome Biol. 7, R61 (2006).
20. Kim, Y.K. et al. Relationship of stereochemical and skeletal diversity of small molecules to cellular measurement space. J. Am. Chem. Soc. 126, 14740-14745 (2004).
21. Franz, A.K., Dreyfuss, P.D. & Schreiber, S.L. Synthesis and cellular profiling of diverse organosilicon small molecules. J. Am. Chem. Soc. 129, 1020-1021 (2007).
22. Larsson, N.G. & Clayton, D.A. Molecular genetic aspects of human mitochondrial disorders. Annu. Rev. Genet. 29, 151-178 (1995).
23. Clayton, D.A. Transcription of the mammalian mitochondrial genome. Annu. Rev. Biochem. 53, 573-594 (1984).
24. Antonetti, D.A., Reynet, C. & Kahn, C.R. Increased expression of mitochondrial-encoded genes in skeletal muscle of humans with diabetes mellitus. J. Clin. Invest. 95, 1383-1388 (1995).
25. Huang, X. et al. Insulin-regulated mitochondrial gene expression is associated with glucose flux in human skeletal muscle. Diabetes 48, 1508-1514 (1999).
26. Heddi, A., Stepien, G., Benke, P.J. & Wallace, D.C. Coordinate induction of energy gene expression in tissues of mitochondrial disease patients. J. Biol. Chem. 274, 22968-22976 (1999).
27. Graham, D.J. et al. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. J. Am. Med. Assoc. 292, 2585-2590 (2004).
28. Dirks, A.J. & Jones, K.M. Statin-induced apoptosis and skeletal myopathy. Am. J. Physiol. 291, C1208-C1212 (2006).
29. van Vliet, A.K., Negre-Aminou, P., van Thiel, G.C., Bolhuis, P.A. & Cohen, L.H. Action of lovastatin, simvastatin, and pravastatin on sterol synthesis and their antiproliferative effect in cultured myoblasts from human striated muscle. Biochem. Pharmacol. 52, 1387-1392 (1996).
30. Frendin, T.J. & Swainson, C.P. Acute renal failure secondary to non-traumatic rhabdomyolysis following amoxapine overdose. N. Z. Med. J. 98, 690-691 (1985).
31. Blessing, W. & Walsh, J.C. Myotonia precipitated by propranolol therapy. Lancet 309, 73-74 (1977).
32. Davidson, B.K. Myositis associated with griseofulvin therapy. Am. Fam. Physician 52, 1277 (1995).
33. Delobel, P. & Pradinaud, R. Rhabdomyolysis associated with pentamidine isethionate therapy for American cutaneous leishmaniasis. J. Antimicrob. Chemother. 51, 1319-1320 (2003).
34. Rowinsky, E.K. et al. Phase I and pharmacologic study of paclitaxel and cisplatin with granulocyte colony-stimulating factor: neuromuscular toxicity is dose-limiting. J. Clin. Oncol. 11, 2010-2020 (1993).
35. Aronson, J.K. Ed. Meyler's Side Effects of Drugs 15th edn. (Elsevier Science, Burlington, Massachusetts, USA, 2006).
36. Bliss, C.I. The toxicity of poisons applied jointly. Ann. Appl. Biol. 26, 585-615 (1939).
37. Kelley, D.E., He, J., Menshikova, E.V. & Ritov, V.B. Dysfunction of mitochondria in human skeletal muscle in type 2 diabetes. Diabetes 51, 2944-2950 (2002).
38. Houstis, N., Rosen, E.D. & Lander, E.S. Reactive oxygen species have a causal role in multiple forms of insulin resistance. Nature 440, 944-948 (2006).
39. Lustbader, J.W. et al. ABAD directly links Aβ to mitochondrial toxicity in Alzheimer's disease. Science 304, 448-452 (2004).
40. Li, W.L., Zheng, H.C., Bukuru, J. & De Kimpe, N. Natural medicines used in the traditional Chinese medical system for therapy of diabetes mellitus. J. Ethnopharmacol. 92, 1-21 (2004).
41. Bonawitz, N.D., Clayton, D.A. & Shadel, G.S. Initiation and beyond: multiple functions of the human mitochondrial transcription machinery. Mol. Cell 24, 813-825 (2006).
42. Wu, Z. et al. Mechanisms controlling mitochondrial biogenesis and respiration through the thermogenic coactivator PGC-1. Cell 98, 115-124 (1999).
43. Mootha, V.K. et al. Errα and Gabpa/b specify PGC-1α-dependent oxidative phosphorylation gene expression that is altered in diabetic muscle. Proc. Natl. Acad. Sci. USA 101, 6570-6575 (2004).
44. Valle, I., Alvarez-Barrientos, A., Arza, E., Lamas, S. & Monsalve, M. PGC-1alpha regulates the mitochondrial antioxidant defense system in vascular endothelial cells. Cardiovasc. Res. 66, 562-573 (2005).
45. Freyssenet, D., Irrcher, I., Connor, M.K., DiCarlo, M. & Hood, D.A. Calcium-regulated changes in mitochondrial phenotype in skeletal muscle cells. Am. J. Phys. 286, 1053-1061 (2004).
46. Caprio, S. et al. Improvement of metabolic control in diabetic patients during mebendazole administration: preliminary studies. Diabetologia 27, 52-55 (1984).
47. Karbowski, M. et al. Opposite effects of microtubule-stabilizing and microtubule-destabilizing drugs on biogenesis of mitochondria in mammalian cells. J. Cell Sci. 114, 281-291 (2001).
48. Mitchell, P. Coupling of phosphorylation to electron and hydrogen transfer by a chemiosmotic type of mechanism. Nature 199, 144-148 (1961).
49. Lee, P.D., Sladek, R., Greenwood, C.M. & Hudson, T.J. Control genes and variability: absence of ubiquitous reference transcripts in diverse mammalian expression studies. Genome Res. 12, 292-297 (2002).
50. Hieronymus, H. et al. Gene expression signature-based chemical genomic prediction identifies a novel class of HSP90 pathway modulators. Cancer Cell 10, 321-330 (2006).